Unicycive Therapeutics (UNCY) Accumulated Expenses (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Accumulated Expenses data on file, last reported at $768000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 81.46% year-over-year to $768000.0; the trailing twelve-month figure through Mar 2026 stood at $768000.0 (down 81.46% YoY), and the FY2025 full-year result was $329000.0, down 82.77% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $768000.0, up from $329000.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $4.1 million in Q1 2025 and bottomed at $329000.0 in Q4 2025.
• The 5-year median for Accumulated Expenses is $1.9 million (2024), against an average of $2.0 million.
• The widest annual swing landed in 2022, when Accumulated Expenses soared 384.2%; it then plunged 82.77% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $1.5 million in 2022, then climbed by 28.92% to $1.9 million in 2023, then declined by 0.37% to $1.9 million in 2024, then slumped by 82.77% to $329000.0 in 2025, then surged by 133.43% to $768000.0 in 2026.
• The last three Accumulated Expenses figures came in at $768000.0 (Q1 2026), $329000.0 (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.

Peer Comparison